利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者 - Suppr | 超能文献

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.

作者信息

Duraes Andre R, Bitar Yasmin S L

机构信息

Universidade Federal da Bahia, Salvador, Brazil

出版信息

N Engl J Med. 2021 Mar 11;384(10):975. doi: 10.1056/NEJMc2035891.

DOI:10.1056/NEJMc2035891

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者

N Engl J Med. 2021 Mar 11;384(10):975. doi: 10.1056/NEJMc2035891.

2

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者

N Engl J Med. 2021 Mar 11;384(10):974-975. doi: 10.1056/NEJMc2035891.

3

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换患者

N Engl J Med. 2021 Mar 11;384(10):974. doi: 10.1056/NEJMc2035891.

4

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者

N Engl J Med. 2021 Mar 11;384(10):973-974. doi: 10.1056/NEJMc2035891.

5

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. Reply.利伐沙班用于心房颤动合并生物瓣二尖瓣置换患者。回复

N Engl J Med. 2021 Mar 11;384(10):975-976. doi: 10.1056/NEJMc2035891.

6

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班在心房颤动合并生物瓣二尖瓣患者中的应用。

N Engl J Med. 2020 Nov 26;383(22):2117-2126. doi: 10.1056/NEJMoa2029603. Epub 2020 Nov 14.

7

In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events.在合并有房颤和生物瓣二尖瓣置换的患者中，利伐沙班用于临床事件时间的非劣效于华法林。

Ann Intern Med. 2021 Apr;174(4):JC43. doi: 10.7326/ACPJ202104200-043. Epub 2021 Apr 6.

8

Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve.利伐沙班，心房颤动合并生物瓣二尖瓣置换术后患者的一种新选择。

Eur Heart J. 2021 Feb 21;42(8):811-812. doi: 10.1093/eurheartj/ehaa1075.

9

Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? - New insights from RIVER trial.房颤合并生物瓣二尖瓣置换术后患者华法林的时代是否即将终结？——RIVER 试验的新见解。

Indian Heart J. 2021 Jul-Aug;73(4):516-517. doi: 10.1016/j.ihj.2021.06.019. Epub 2021 Jul 1.

10

Oral anticoagulation is not necessary for patients with bioprosthetic mitral valve replacement in atrial fibrillation.对于接受生物瓣二尖瓣置换术且合并房颤的患者，无需进行口服抗凝治疗。

Z Kardiol. 1986;75 Suppl 2:321-5.

引用本文的文献

1

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Compared with Vitamin K Antagonists in Patients with Atrial Fibrillation and Type 2 Valvular Heart Disease: A Systematic Review and Meta-Analysis.非维生素K拮抗剂口服抗凝药与维生素K拮抗剂在心房颤动合并2型瓣膜性心脏病患者中的疗效和安全性：一项系统评价和荟萃分析

Cardiovasc Drugs Ther. 2024 Aug 17. doi: 10.1007/s10557-024-07616-7.